Regal Investment Advisors LLC boosted its position in shares of Humana Inc (NYSE:HUM) by 16.8% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,960 shares of the insurance provider’s stock after buying an additional 1,003 shares during the quarter. Regal Investment Advisors LLC’s holdings in Humana were worth $2,356,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in the stock. FMR LLC boosted its stake in Humana by 12.7% during the second quarter. FMR LLC now owns 12,212,514 shares of the insurance provider’s stock valued at $3,634,811,000 after buying an additional 1,374,030 shares in the last quarter. Northern Trust Corp boosted its stake in Humana by 1.2% during the second quarter. Northern Trust Corp now owns 1,687,211 shares of the insurance provider’s stock valued at $502,164,000 after buying an additional 20,480 shares in the last quarter. Acadian Asset Management LLC boosted its stake in Humana by 7.6% during the second quarter. Acadian Asset Management LLC now owns 1,324,681 shares of the insurance provider’s stock valued at $394,262,000 after buying an additional 93,021 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Humana by 4.7% during the third quarter. Massachusetts Financial Services Co. MA now owns 804,090 shares of the insurance provider’s stock valued at $272,199,000 after buying an additional 35,845 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its stake in Humana by 1.1% during the second quarter. Schwab Charles Investment Management Inc. now owns 582,738 shares of the insurance provider’s stock valued at $173,441,000 after buying an additional 6,522 shares in the last quarter. 92.62% of the stock is owned by institutional investors and hedge funds.
HUM has been the subject of several research reports. Morgan Stanley initiated coverage on Humana in a research note on Thursday, July 12th. They set an “overweight” rating and a $362.00 target price for the company. Royal Bank of Canada reaffirmed a “hold” rating and set a $318.00 target price on shares of Humana in a report on Thursday, August 2nd. Jefferies Financial Group upped their target price on Humana from $356.00 to $372.00 and gave the company a “buy” rating in a report on Thursday, August 2nd. Bank of America upped their target price on Humana from $338.00 to $375.00 and gave the company a “buy” rating in a report on Thursday, August 2nd. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $355.00 target price on shares of Humana in a report on Thursday, August 2nd. Seven equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $343.35.
Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.29 by $0.29. The firm had revenue of $14.21 billion during the quarter, compared to the consensus estimate of $13.97 billion. Humana had a return on equity of 17.43% and a net margin of 2.48%. During the same period in the prior year, the business earned $3.39 EPS. On average, research analysts anticipate that Humana Inc will post 14.18 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 25th. Investors of record on Monday, December 31st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 0.57%. The ex-dividend date is Friday, December 28th. Humana’s dividend payout ratio is currently 17.08%.
In related news, insider Elizabeth D. Bierbower sold 3,092 shares of the stock in a transaction dated Thursday, August 16th. The stock was sold at an average price of $330.00, for a total value of $1,020,360.00. Following the completion of the sale, the insider now directly owns 14,289 shares of the company’s stock, valued at approximately $4,715,370. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Bruce D. Broussard sold 18,000 shares of the stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $328.66, for a total value of $5,915,880.00. Following the completion of the sale, the chief executive officer now directly owns 71,085 shares of the company’s stock, valued at $23,362,796.10. The disclosure for this sale can be found here. 0.60% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Regal Investment Advisors LLC Increases Position in Humana Inc (HUM)” was first reported by WKRB News and is the property of of WKRB News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.wkrb13.com/2018/11/09/regal-investment-advisors-llc-increases-position-in-humana-inc-hum.html.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.